Loading data for NAGE — first visit, this takes a few seconds.

Niagen Bioscience, Inc. (NAGE)

NasdaqCM: NAGE · Real-Time Price · USD

3.17

+0.06 (1.93%)

At close: Sep 11, 2026, 3:59 PM

3.04

+0.00%

After-hours: 4:10 PM

Alert

The price, the headline numbers and the latest news, in one place.

1.93% (1D)

Bid	2.24
Market Cap	240M
Revenue (ttm)	129M
Net Income (ttm)	16M
	2.09
	0.19
	15.97
	30.35
P/B (ttm)	2.91
P/S (ttm)	1.87
Earnings Date	Mar 6, 2024

Ask	3.94
Volume	256,765
Avg. Volume (20D)	658,106
Open	3.10
Previous Close	3.11
Day's Range	3.07 - 3.17
52-Week Range	2.87 - 10.52
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About NAGE

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercial...

[Read more]

Industry Packaged Foods

Sector Consumer Defensive

IPO Date Jun 25, 2008

Employees 117

Stock Exchange NasdaqCM

Ticker Symbol NAGE

Website https://www.niagenbioscience.com

Full Company Profile

Financial Performance

In 2025, Niagen Bioscience's revenue was 129.42M, an increase of 29.95% compared to the previous year's 99.6M. Earnings were 17.38M, an increase of 103.3%.

Financial Statements

Earnings Surprise

Niagen Bioscience has released their quarterly earnings on Aug 4, 2026:

Revenue of $29.79M misses estimates by $0, with -4.28% YoY decline.
EPS of 0.01 exceeds estimates by 0.02, with -75.00% YoY decline.

Next Earnings Release

Niagen Bioscience, Inc. is scheduled to release its earnings on Mar 6, 2024, after market closes.
Analysts project revenue of ... Upgrade

Why Price Moved

News

1 month ago · Simply Wall St.

Does Niagen Bioscience's (NAGE) Walmart NAD+ Push Redefine Its Healthy‑Aging Brand Narrative?

In early August 2026, Niagen Bioscience Inc. reported slightly lower quarterly sales and net income year on year, while also expanding access to its Tru Niagen® healthy‑aging NAD+ supplement via Walma...

1 month ago · Simply Wall St.

Niagen Bioscience (NAGE) On New Aging Study And The Case For A Higher Fair Value

Niagen Bioscience (NAGE) is back in focus after a new peer reviewed study reported that its Niagen nicotinamide riboside supplementation was associated with reduced muscle epigenetic age acceleration ...

1 month ago · GuruFocus.com

Niagen Bioscience Inc (NAGE) (Q2 2026) Earnings Call Highlights: E-Commerce Surge and China ...

Niagen Bioscience Inc (NAGE) reports strong TrueNiagen sales growth, China cross-border revenue exceeding full-year 2025 totals, and advances in pharmaceutical pipeline with promising PRV potential.

1 month ago · Zacks

Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates

Niagen Bioscience (NAGE) delivered earnings and revenue surprises of 0.00% and -0.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2 months ago · Zacks

Implied Volatility Surging for Niagen Bioscience Stock Options

Investors need to pay close attention to NAGE stock based on the movements in the options market lately.

Page 1 of 2

Niagen Bioscience, Inc. (NAGE)